51 related articles for article (PubMed ID: 16200613)
1. Mapping the dose-effect relationship of orbofiban from sparse data with an artificial neural network.
Mager DE; Shirey JD; Cox D; Fitzgerald DJ; Abernethy DR
J Pharm Sci; 2005 Nov; 94(11):2475-86. PubMed ID: 16200613
[TBL] [Abstract][Full Text] [Related]
2. Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes.
Cox D; Smith R; Quinn M; Theroux P; Crean P; Fitzgerald DJ
J Am Coll Cardiol; 2000 Nov; 36(5):1514-9. PubMed ID: 11079651
[TBL] [Abstract][Full Text] [Related]
3. Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as a determinant of the responses to an oral GPIIb/IIIa antagonist in patients with unstable coronary syndromes.
O'Connor FF; Shields DC; Fitzgerald A; Cannon CP; Braunwald E; Fitzgerald DJ
Blood; 2001 Dec; 98(12):3256-60. PubMed ID: 11719362
[TBL] [Abstract][Full Text] [Related]
4. Role of oral blockade of platelet glycoprotein IIb/IIIa on neutrophil activation in patients with acute coronary syndromes.
Serrano CV; Nicolau JC; Venturinelli M; Baracioli LM; Anders RJ; Cannon CP; Ramires JA
Cardiovasc Drugs Ther; 2003 Mar; 17(2):129-32. PubMed ID: 12975594
[TBL] [Abstract][Full Text] [Related]
5. Orbofiban: an orally active GPIIb/IIIa platelet receptor antagonist.
Nicholson NS; Abood NA; Panzer-Knodle SG; Frederick LG; Page JD; Salyers AK; Suleymanov OD; Szalony JA; Taite BB; Anders RJ
Med Res Rev; 2001 May; 21(3):211-26. PubMed ID: 11301411
[TBL] [Abstract][Full Text] [Related]
6. Antiplatelet and antithrombotic effects of orbofiban, a new orally active GPIIb/IIIa antagonist, in guinea pigs.
Ogawa T; Sugidachi A; Naganuma H; Asai F
Thromb Res; 2000 Mar; 97(5):307-15. PubMed ID: 10709906
[TBL] [Abstract][Full Text] [Related]
7. Xemilofiban/orbofiban: insight into drug development.
Anders R; Kleiman J; Nicholson N; Wazowicz B; Burns D
Cardiovasc Drug Rev; 2001; 19(2):116-32. PubMed ID: 11484066
[TBL] [Abstract][Full Text] [Related]
8. Prior peripheral arterial disease and cerebrovascular disease are independent predictors of adverse outcome in patients with acute coronary syndromes: are we doing enough? Results from the Orbofiban in Patients with Unstable Coronary Syndromes-Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study.
Cotter G; Cannon CP; McCabe CH; Michowitz Y; Kaluski E; Charlesworth A; Milo O; Bentley J; Blatt A; Krakover R; Zimlichman R; Reisin L; Marmor A; Lewis B; Vered Z; Caspi A; Braunwald E;
Am Heart J; 2003 Apr; 145(4):622-7. PubMed ID: 12679757
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy between the glycoprotein IIb/IIIa antagonists roxifiban and orbofiban in inhibiting platelet responses in flow models of thrombosis.
Mousa SA; Abulencia JP; McCarty OJ; Turner NA; Konstantopoulos K
J Cardiovasc Pharmacol; 2002 Apr; 39(4):552-60. PubMed ID: 11904529
[TBL] [Abstract][Full Text] [Related]
10. Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation; a phase II study.
Akkerhuis KM; Neuhaus KL; Wilcox RG; Vahanian A; Boland JL; Hoffmann J; Baardman T; Nehmiz G; Roth U; Klootwijk AP; Deckers JW; Simoons ML;
Eur Heart J; 2000 Dec; 21(24):2042-55. PubMed ID: 11102255
[TBL] [Abstract][Full Text] [Related]
11. Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome: an OPUS-TIMI 16 substudy. Orbofiban in Patients with Unstable coronary syndromes. Thrombolysis In Myocardial Infarction.
Holmes MB; Sobel BE; Cannon CP; Schneider DJ
Am J Cardiol; 2000 Feb; 85(4):491-3, A10. PubMed ID: 10728957
[TBL] [Abstract][Full Text] [Related]
12. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials.
Boersma E; Harrington RA; Moliterno DJ; White H; Théroux P; Van de Werf F; de Torbal A; Armstrong PW; Wallentin LC; Wilcox RG; Simes J; Califf RM; Topol EJ; Simoons ML
Lancet; 2002 Jan; 359(9302):189-98. PubMed ID: 11812552
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and concentration-effect analysis of intravenous RGD891, a platelet GPIIb/IIIa antagonist, using mixed-effects modeling (NONMEM).
Zannikos PN; Rohatagi S; Jensen BK; DePhillips SL; Rhodes GR
J Clin Pharmacol; 2000 Oct; 40(10):1129-40. PubMed ID: 11028252
[TBL] [Abstract][Full Text] [Related]
14. Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial.
Sabatine MS; Morrow DA; Giugliano RP; Murphy SA; Demopoulos LA; DiBattiste PM; Weintraub WS; McCabe CH; Antman EM; Cannon CP; Braunwald E
Circulation; 2004 Feb; 109(7):874-80. PubMed ID: 14757697
[TBL] [Abstract][Full Text] [Related]
15. Abciximab pharmacodynamic model with neural networks used to integrate sources of patient variability.
Urquidi-Macdonald M; Mager DE; Mascelli MA; Frederick B; Freedman J; Fitzgerald DJ; Kleiman NS; Abernethy DR
Clin Pharmacol Ther; 2004 Jan; 75(1):60-9. PubMed ID: 14749692
[TBL] [Abstract][Full Text] [Related]
16. A cold start for oral glycoprotein IIb/IIIa antagonists.
Curtin R; Fitzgerald DJ
Eur Heart J; 2000 Dec; 21(24):1992-4. PubMed ID: 11102247
[No Abstract] [Full Text] [Related]
17. A population pharmacokinetic-pharmacodynamic and logistic regression analysis of lotrafiban in patients.
Mould D; Chapelsky M; Aluri J; Swagzdis J; Samuels R; Granett J
Clin Pharmacol Ther; 2001 Apr; 69(4):210-22. PubMed ID: 11309549
[TBL] [Abstract][Full Text] [Related]
18. Statins are associated with lower risk of gastrointestinal bleeding in patients with unstable coronary syndromes: analysis of the Orbofiban in Patients with Unstable coronary Syndromes-Thrombolysis In Myocardial Infarction 16 (OPUS-TIMI 16) trial.
Atar S; Cannon CP; Murphy SA; Rosanio S; Uretsky BF; Birnbaum Y
Am Heart J; 2006 May; 151(5):976.e1-6. PubMed ID: 16644315
[TBL] [Abstract][Full Text] [Related]
19. Modulation of platelet-neutrophil interaction with pharmacological inhibition of fibrinogen binding to platelet GPIIb/IIIa receptor.
Xiao Z; Théroux P; Frojmovic M
Thromb Haemost; 1999 Feb; 81(2):281-5. PubMed ID: 10064007
[TBL] [Abstract][Full Text] [Related]
20. Treatment with a GPIIb/IIIa antagonist inhibits thrombin generation in platelet rich plasma from patients.
Keularts IM; Béguin S; de Zwaan C; Hemker HC
Thromb Haemost; 1998 Sep; 80(3):370-1. PubMed ID: 9759611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
